Jun 23, 2026
This podcast was developed by AMJ in collaboration with GSK and is sponsored by GSK. This information is scientific and non-promotional in nature, and intended for US audiences.
Less than 20% of biologic-eligible patients with GINA Step 5 asthma receive biologic therapy.1,2 In this AMJ podcast, experts discuss how real-world gaps in initiation, access, and adherence can affect whether patients start, stay on, and sustain benefit from biologic therapy over time.
Listen to the full episode to explore:
- Key real-world data on biologic initiation and adherence in severe asthma
- Patient cases showing common barriers across the care pathway
- Practical ways to uncover the burden of severe asthma
- The Start, Stay, Sustain framework for patient-centered care
Speakers:
- Justin Kwiatek, US Medical Affairs Lead, Respiratory Biologics, GSK
- Tom Corbridge, US Senior Medical Director, Respiratory Biologics, GSK
References
- Park J et al. Biologic underutilization and healthcare burden in US patients with Type 2 severe asthma. J Asthma Allergy. 2026;19:580937.
- Maselli DJ et al. Patient characteristics and social determinants of health influence adherence to biologic therapy for asthma. SEAAIS 80th Annual Meeting, October 23-26, 2025.